Skin Neoplasms Pipeline Analysis Report 2026

Skin neoplasms represent a diverse group of malignant and pre-malignant lesions affecting the skin, ranging from basal cell carcinoma to advanced melanoma. According to the International Agency for Research on Cancer, nearly 330,000 new melanoma cases and about 60,000 related deaths were reported globally in 2022, highlighting a growing public health concern. The skin neoplasms pipeline analysis reveals robust development activity, with numerous immunotherapies, targeted agents, and combination treatments, signaling a promising future for emerging therapies for skin neoplasms treatment.

Report Coverage

The Skin Neoplasms Pipeline Analysis Report gives comprehensive insights into skin neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for skin neoplasms. The skin neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The skin neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with skin neoplasms treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to skin neoplasms.

Skin Neoplasms Pipeline Outlook

Skin neoplasms are abnormal growths of skin cells that may be benign or malignant, including conditions such as melanoma and non-melanoma cancers. They develop due to uncontrolled cell division, primarily triggered by prolonged ultraviolet radiation exposure, genetic mutations, and environmental factors, which can lead to tissue damage and potential spread if not treated early.

Skin neoplasms treatment includes surgical removal, radiation therapy, and systemic approaches. Current advancements emphasize novel drugs in skin cancer pipeline development, targeted therapy pipeline for skin neoplasms, and biologics in skin neoplasm drug development to improve outcomes. A notable development occurred in November 2025, the European Union approval of Libtayo (cemiplimab) as the first and only immunotherapy for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation, based on compelling Phase 3 data showing significant reduction in recurrence risk, expanding options for earlier intervention in skin cancer management.

Skin Neoplasms Epidemiology

The pipeline reflects a growing need driven by rising incidence rates globally. According to the International Agency for Research on Cancer, approximately 330,000 new melanoma cases and 60,000 related deaths were reported in 2022. As per Binaytara, melanoma accounts for only 1% of cases but causes over 80% of deaths. According to Xiaoyu He et al., 2023, over 5 million cases are diagnosed annually in the United States. In India, as per Shital Tanaji Jadhav et al., 2023, skin neoplasms represent 2-3% of cancers, supporting continued pipeline advancements.

Skin Neoplasms - Pipeline Therapeutic Assessment

This section of the report covers the analysis of skin neoplasms drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The skin neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Skin Neoplasms Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total skin neoplasms clinical trials. Phase I (31%), Phase II (48%), Phase III (16%) collectively highlight a strong concentration of clinical activity in early- and mid-stage development. This distribution indicates a strong emphasis on mid‑stage development, particularly Phase 2 trials, reflecting a robust focus on efficacy evaluation and optimization before late‑stage approval. The pipeline outlook remains dynamic, with immunotherapies and targeted treatments leading innovation.

Skin Neoplasms Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the skin neoplasms pipeline analysis include small molecules, monoclonal antibodies, and peptides. The skin neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for skin neoplasms. For instance, in February 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Amtagvi (lifileucel), marking the first FDA‑approved cellular therapy for unresectable or metastatic melanoma in adults previously treated with standard therapies. This tumor‑infiltrating lymphocyte (TIL)‑based immunotherapy offers a novel option for patients with advanced melanoma that cannot be removed surgically or has spread, addressing a significant unmet need in solid tumor treatment.

Skin Neoplasms Clinical Trials - Key Players

The report for the skin neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides detailed skin neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in skin neoplasms clinical trials:

• GlaxoSmithKline
• Phio Pharmaceuticals Inc.
• Merck Sharp & Dohme LLC
• Exelixis
• Genentech, Inc.
• Boehringer Ingelheim
• Guangzhou FineImmune Biotechnology Co., Ltd.
• Biocad
• Degron Therapeutics Co.
• Stella Pharma Corporation
• Vector Vitale LLC
• Iovance Biotherapeutics, Inc.

Skin Neoplasms - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for skin neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of skin neoplasms drug candidates.

Drug: GSK2636771

GSK2636771 is an oral, selective PI3K-β inhibitor designed to target PI3K pathway-driven skin neoplasms, particularly those with PTEN loss. By blocking PI3K-β-mediated tumor proliferation and survival signaling, it aims to reduce malignant cell growth and enhance sensitivity to other targeted therapies. The drug is being developed by GlaxoSmithKline (GSK), a global leader in oncology innovation with an active pipeline in precision medicine and immuno-oncology. GSK continues to conduct clinical studies exploring its role across multiple solid tumors.

Drug: PH-762

PH-762 is an investigational RNA interference (RNAi) therapeutic being developed by Phio Pharmaceuticals Inc. for the treatment of skin neoplasms, including squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The Phase 1 study is evaluating the safety, tolerability, pharmacokinetics, and tumor response of this drug. PH-762 is being administered via intratumoral injection, where it is directly silencing PD-1 mRNA to enhance localized anti-tumor immune activity while minimizing systemic toxicity. The study is being conducted in a neoadjuvant setting, with completion expected by March 2026.

Biological: OBX-115

OBX-115 is an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy engineered with membrane-bound IL-15, designed to enhance T-cell persistence and antitumor activity in skin neoplasms such as metastatic melanoma. Sponsored by Obsidian Therapeutics, Inc., the Phase 1/2 Agni-01 study is evaluating safety, tolerability, and preliminary efficacy using objective response rates. The therapy is being administered via infusion, leveraging a regulated IL-15 mechanism to improve immune response. The study is expected to be completed in June 2028, while further assessing survival outcomes and disease control rates.

Key Questions Answered in the Skin Neoplasms Pipeline Insight Report

• Which companies/institutions are leading the skin neoplasms drug development?
• Which company is leading the skin neoplasms pipeline development activities?
• What is the current skin neoplasms commercial assessment?
• What are the opportunities and challenges present in the skin neoplasms pipeline landscape?
• What is the efficacy and safety profile of skin neoplasms pipeline drugs?
• Which company is conducting major trials for skin neoplasms drugs?
• Which companies/institutions are involved in skin neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in skin neoplasms?

Reasons To Buy This Report

The skin neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for skin neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into skin neoplasms collaborations, regulatory environments, and potential growth opportunities.